1. Home
  2. VHC vs ANL Comparison

VHC vs ANL Comparison

Compare VHC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VirnetX Holding Corp

VHC

VirnetX Holding Corp

HOLD

Current Price

$22.03

Market Cap

79.2M

Sector

Miscellaneous

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$1.10

Market Cap

52.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VHC
ANL
Founded
2005
2004
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Multi-Sector Companies
Sector
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
79.2M
52.0M
IPO Year
1999
2023

Fundamental Metrics

Financial Performance
Metric
VHC
ANL
Price
$22.03
$1.10
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
14.6K
17.8K
Earning Date
11-14-2025
04-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$106,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2020.00
N/A
52 Week Low
$3.68
$0.88
52 Week High
$29.00
$2.99

Technical Indicators

Market Signals
Indicator
VHC
ANL
Relative Strength Index (RSI) 53.08 36.49
Support Level $18.21 $1.32
Resistance Level $23.70 $1.59
Average True Range (ATR) 1.92 0.18
MACD -0.33 -0.04
Stochastic Oscillator 56.77 31.12

Price Performance

Historical Comparison
VHC
ANL

About VHC VirnetX Holding Corp

VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: